Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain MetastasesClin. Cancer Res 2023 Feb 01;29(3)521-531, JS Wilmott, H Tawbi, JA Engh, NM Amankulor, B Shivalingam, H Banerjee, IA Vergara, H Lee, PA Johansson, PM Ferguson, P Saiag, C Robert, JJ Grob, LH Butterfield, RA Scolyer, JM Kirkwood, GV Long, MA Davies
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.